The future of precision medicine part 5: keeping pace with regulation

The first four instalments in this series of articles on precision medicine focused on its challenges and opportunities in general, the importance of large quantities of high quality, diverse data, and some of the particular issues that will be encountered in the translation of research and theory to clinical practice.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

China-origin biotech assets and the hidden question of IP ownership

27 August 2026 As China-origin biotech assets flood the market, licensing deals are booming. Yet, the real strategic battle isn't just about the science—it’s about who controls the underlying IP, says Paul Calvo of Sterne Kessler

Biotech

10x Genomics dealt major blow in sequencing fight

20 August 2026 Three disputed sequencing patents took the spotlight as the Federal Circuit weighed challenges to a trio of PTAB rulings.

Biotech

Europe’s missing biotech bridge: Why IP ownership matters more than capital access

17 August 2026 Europe’s biotechnology challenge is not only whether it can fund innovation. It is whether it can continue to originate and control the foundational IP positions from which future biotech value is created. Paul Calvo of Sterne Kessler explains.

More features

FDA targets faster generic approvals in drive to slash drug prices

China-origin biotech assets and the hidden question of IP ownership

The buyers' wishlist: What makes a life sciences deal stack up?

Stris & Maher opens new Dallas office with partner hires

10x Genomics dealt major blow in sequencing fight

SK Biopharmaceuticals settles epilepsy generic dispute

Vanda revives challenge over braille-free label on generic sleep disorder drug

Abbott fends off Chinese rival’s patent challenge at UPC

The future of precision medicine part 5: keeping pace with regulation

More on this story

Editor's picks

Editor's picks

More features